The Irish Times view on cannabis: a debate long overdue
The research base on cannabis is skimpy, largely due to its illegal status, but there is some evidence of its usefulness for treating a limited number of ailments
The controversy over cannabis, which has been re-ignited this week by the warnings from senior doctors about its dangers, is really several debates in one. But as the doctors in the Cannabis Risk Alliance pointed out, the boundaries between these debates – on the recreational versus medicinal uses of the drug; and on legalisation versus decriminalisation – have become blurred.
In the absence of leadership from politicians and medics, there has been remarkably little public discussion on cannabis in recent years. This is particularly striking given the liberalisation of laws governing its use in a number of western countries, and many US states. Here, the Government is due to consider the report of a working group on the issue within weeks. This is likely to suggest a switch in emphasis to drug counselling and addiction treatment in cases of personal possession rather than criminal sanction.
Cannabis has changed immeasurably; today’s drug, grown in carefully controlled hot-house conditions, is far more potent than the grass or hash that was common a few decades ago. The dangers associated with it have grown apace, but corresponding awareness does not seem to have penetrated the public consciousness.
Campaigners for medical cannabis have taken offence at the implication that their work is a 'Trojan horse' for wider legalisation of the drug
What debate there has been has focused on the medicinal uses of the plant. The research base on cannabis is skimpy, largely due to its illegal status, but there is some evidence of its usefulness for treating a limited number of ailments. Parents of children with severe epilepsy, for example, have spoken of the huge difference medicinal cannabis has made in reducing seizures and improving quality of life. Other claims – for example, its ability to “cure” cancer – are simply without foundation.
Campaigners for medical cannabis have taken offence at the implication that their work is a “Trojan horse” for wider legalisation of the drug. Yet the favourable attention paid to their cause cast the drug in a softer light. The result was an imbalance in public debate, one that is now being corrected by the willingness of frontline doctors to talk about the cannabis-related problems they are encountering in their practice. In this regard, it would be helpful to hear more from the chief medical officer in Ireland’s Department of Health.
The State has moved slowly to provide an access scheme for medicinal cannabis, which is now likely to start in the coming months. This will allow for the drug, supplied by quality assured and approved suppliers only, to be prescribed for patients for a limited number of conditions, where they have no other treatment options. The caution involved has irked campaigners, but given the gaps in evidence and the potential harms involved, it is hard to see how else the Department could have proceeded.